Skip to content

AMI Co., Ltd. Selected for accelerator trial by Fogarty Innovation and Mitsubishi Corporation North America in Silicon Valley, USA

AMI Co., Ltd.
Selected for an accelerator trial by Fogarty Innovation and Mitsubishi Corporation North America in Silicon Valley, USA

AMI Co., Ltd. (hereinafter “our company”) has become a trial company for the accelerator program run by Mitsubishi Corporation North America (hereinafter “MCA”) in Silicon Valley, the United States, with the aim of supporting Japanese startups entering the United States. Elected. Our resident team will be based in a 2,800 square meter incubation center owned by Fogarty Innovation (a non-profit Medtech incubator), working directly with MCA and Fogarty Innovation to develop business in the United States during the program period. We formulate and promote strategies and regulatory affairs strategies. We are the only medical device company selected for the trial by the MCA. [Image

[Purpose] Formulation of business and regulatory strategies in the United States [Period] From October 2022 (4 months)
[Place] Silicon Valley (Mountain View, California, USA)
-Comments from the person in charge regarding the development of this project- AMI Co., Ltd. CEO Shinpei Ogawa
We are honored to be the only company in Japan to be selected after a rigorous screening process, out of many medical device businesses that are considering global expansion. We will take the first step to expand from Silicon Valley, where famous startups continue to be born, to North America and the world.
Mr. Shotaro Wakasa, Director of Healthcare Business Development, Mitsubishi Corporation (Americas)
We are pleased to be able to support AMI’s overseas expansion through this program. We would like to contribute to the revitalization of Japan’s industrial and innovation ecosystem by supporting startups that develop groundbreaking solutions to enter the United States and promoting the globalization of Japanese technologies and services. Fogarty Innovation Chief Commercial Strategy Officer Marga Ortigas-Wedekind With careful consideration of the appropriate market to step into and a better understanding of the resources required to navigate the complex regulatory environment, AMI has prepared and deliberated to ensure a well-prepared entry into the U.S. market. I work hard every day. It’s a pleasure to work with such an enthusiastic and motivated team as AMI.
-Company Profile-
AMI Co., Ltd.
A research and development startup with the mission of “realizing rapid medical innovation”. Based on the conviction that we can deliver innovative medical care to the world by maximizing technology, we are developing a new D-to-D (Doctor to Doctor) telemedicine service and comprehensive cloud services. Aiming to realize the hospital concept. URL:
Mitsubishi Corporation North America, Inc.
A US subsidiary of Mitsubishi Corporation. Mitsubishi Corporation conducts business in cooperation with offices in approximately 90 countries and regions around the world and approximately 1,700 consolidated operating companies. Businesses in a wide range of industries with a structure that includes 10 groups: natural gas, general materials, petroleum and chemical solutions, metal resources, industrial infrastructure, automobiles and mobility, food industry, consumer industry, power solutions, and urban development. In addition to trading, we also play a role in development, production, and manufacturing at sites around the world with our partners.
Fogarty Innovation
Founded by world-renowned cardiac surgeon, inventor, and entrepreneur Thomas J. Fogarty, MD, a non-profit Medtech incubator that provides education to improve the health of people around the world.
Experienced staff support start-up companies to commercialize medical technology through “full-contact mentoring”. In addition, it provides hands-on educational programs across the ecosystem to accelerate the “creation, development, deployment” and clinical application of new medical technologies. Based at El Camino Hospital in Mountain View, California.
For other inquiries, please use the contact page.

Details about this release: